Who are Xolair® + Symbicort®'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xolair-symbicort.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Xolair® + Symbicort® — Competitive Intelligence Brief

Xolair® + Symbicort® (Xolair® + Symbicort®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination. Area: Asthma.

phase 3 Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination IgE receptor Asthma Biologic Live · refreshed every 30 min

Target snapshot

Xolair® + Symbicort® (Xolair® + Symbicort®) — AO GENERIUM. Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xolair® + Symbicort® TARGET	Xolair® + Symbicort®	AO GENERIUM	phase 3	Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination	IgE receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination class)

AO GENERIUM · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xolair® + Symbicort® — Competitive Intelligence Brief. https://druglandscape.com/ci/xolair-symbicort. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab